Supplementary Figure S1-S9 from FUS–DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma

Authors:
  • MTMarcel Trautmann
    Marcel Trautmann
  • JMJasmin Menzel
    Jasmin Menzel
  • CBChristian Bertling
    Christian Bertling
  • MCMagdalene Cyra
    Magdalene Cyra
  • IIIlka Isfort
    Ilka Isfort
  • KSKonrad Steinestel
    Konrad Steinestel
  • SESandra Elges
    Sandra Elges
  • IGInga Grünewald
    Inga Grünewald
  • BABianca Altvater
    Bianca Altvater
  • CRClaudia Rossig
    Claudia Rossig
  • SFStefan Fröhling
    Stefan Fröhling
  • SHSusanne Hafner
    Susanne Hafner
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure (S1): Activation of the IGF-IR and PI3K/Akt/GSK-3beta signaling cascade in representative myxoid liposarcoma cell lines. (S2): Representative sequencing results of PIK3CA mutation hotspots. (S3): IGF-II-effected rescue of PI3K/Akt/GSK-3beta pathway activation in FUS-DDIT3 depleted myxoid liposarcoma cells. (S4): RNAi-mediated reduction of FUS-DDIT3 oncoprotein levels. (S5): Expression and activation levels of IGF-IR and PI3K/Akt/GSK-3beta signaling effectors in A673 and Capan-1 cells. (S6): In vitro and in vivo evaluation of PPP in MLS cells. (S7): Time dependent reduction of Cyclin D1 protein levels. (S8): Flow cytometric analyses in MLS1765-92 cells. (S9): Representative CAM explants (NVP AEW541, MLS402-91 cells).